Tandem Diabetes Care | TNDM - Beneficio Bruto En Ventas





Beneficio Bruto En Ventas Cambio Fecha
Abbott USD 6.54B 625M 2025-12
Accuray USD 41.89M 7.42M 2024-12
Align Technology USD 683.59M 44.39M 2025-12
AtriCure USD 105.34M 4M 2025-12
Baxter International USD 577M 373M 2025-12
Becton, Dickinson and Co. USD 2.41B 1.72B 2025-12
Boston Scientific USD 3.68B 136M 2025-12
Cooper Companies USD 695.2M 44.4M 2025-12
Dexcom USD 792.7M 61.3M 2025-12
Edwards Lifesciences USD 1.23B 18.7M 2025-12
Eli Lilly USD 14.59B 1.48B 2025-09
Globus Medical USD 535.95M 49.28M 2025-12
ICU Medical USD 202.98M 2.1M 2025-12
Inogen USD 41.34M 1.39M 2024-09
Insulet USD 568.6M 58.5M 2025-12
Integra LifeSciences USD 217.1M 10.11M 2025-12
Intuitive Surgical USD 1.9B 241.9M 2025-12
J&J USD 16.6B 118M 2025-12
Masimo USD 247.3M 16.7M 2025-12
Medtronic USD 5.41B 27M 2025-12
Merit Medical Systems USD 195.35M 8.94M 2025-12
Orthofix International USD 153.28M 4.76M 2025-12
Roche Holding CHF 22.09B 10.04B 2025-12
Stryker USD 4.49B 633M 2025-12
Tandem Diabetes Care USD 167.46M 33.17M 2025-12
Teleflex USD 307.45M 144.2M 2025-12
Zimmer Biomet Holdings USD 1.27B 8.1M 2025-12